| Predicate |
Object |
| contentType |
Journal Article|Review |
| endingPage |
100 |
| issn |
0023-2157 |
| issueIdentifier |
1-3 |
| pageRange |
97-100 |
| publicationName |
Klinika oczna |
| startingPage |
97 |
| bibliographicCitation |
Wylegała E, Teper SJ. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment]. Klin Oczna. 2007;109(1-3):97–100. PMID: 17687925. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32c5a24fd7871dba30a03f336a08c71c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_087ee60b7116a7732d1ed405bf410064 |
| date |
2007 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/17687925 |
| isPartOf |
https://portal.issn.org/resource/ISSN/0023-2157
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5437 |
| language |
Polish |
| source |
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
[VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment] |
| discusses |
http://id.nlm.nih.gov/mesh/M0481787
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0479289
http://id.nlm.nih.gov/mesh/M0483498
http://id.nlm.nih.gov/mesh/M0356369
http://id.nlm.nih.gov/mesh/M0328153 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D042461Q000378
http://id.nlm.nih.gov/mesh/D012160Q000187
http://id.nlm.nih.gov/mesh/D008268Q000188
http://id.nlm.nih.gov/mesh/D052157Q000494
http://id.nlm.nih.gov/mesh/D020533Q000494
http://id.nlm.nih.gov/mesh/D000911Q000494 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D016032
http://id.nlm.nih.gov/mesh/D008268Q000503
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D000069579 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8397
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56603655 |